Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer

BMC Clinical Pathology

Volumn 14, Issue 1, 2014, Pages

  Poyet, Cédric ^a   Jentsch, Bastian ^a   Hermanns, Thomas ^a   Schweckendiek, Daniel ^a   Seifert, Hans Helge ^a,c   Schmidtpeter, Martin ^a   Sulser, Tullio ^a   Moch, Holger ^a   Wild, Peter J ^a   Kristiansen, Glen ^b  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BONN   (Germany)

^c Hegau Bodensee Hospital   (Germany)

Author keywords

Class I HDACs; Molecular markers; Urothelial cancer

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; UNIVARIATE ANALYSIS; UROTHELIAL BLADDER CANCER;

EID: 84899106766     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-14-10     Document Type: Article

References (37)

1. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Epstein JI, Amin MB, Reuter VR, Mostofi FK, Am J Surg Pathol 1998 22 12 1435 1448 10.1097/00000478-199812000-00001 9850170
2. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C, J Clin Oncol 2006 24 5 778 789 10.1200/JCO.2005.03.2375 16432078
3. Pathology of transitional cell carcinoma of the bladder and its clinical implications. Lapham RL, Ro JY, Staerkel GA, Ayala AG, Semin Surg Oncol 1997 13 5 307 318 10.1002/(SICI)1098-2388(199709/10)13:5<307::AID-SSU4>3.0.CO;2-H 9259086
4. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Juffs HG, Moore MJ, Tannock IF, Lancet Oncol 2002 3 12 738 747 10.1016/S1470-2045(02)00930-0 12473515
5. HDAC family: what are the cancer relevant targets? Witt O, Deubzer HE, Milde T, Oehme I, Cancer Lett 2009 277 1 8 21 10.1016/j.canlet.2008.08.016 18824292
6. Chemical phylogenetics of histone deacetylases. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R, Nat Chem Biol 2010 6 3 238 243 10.1038/nchembio.313 20139990
7. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G, British journal of cancer 2008 98 3 604 610 10.1038/sj.bjc.6604199 18212746
8. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Wilson AJ, Byun DS, Popova N, Murray LB, L'Italien K, Sowa Y, Arango D, Velcich A, Augenlicht LH, Mariadason JM, The Journal of biological chemistry 2006 281 19 13548 13558 10.1074/jbc.M510023200 16533812
9. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G, Veerla S, Ryden T, Mansson W, Liedberg F, Höglund M, Cancer Res 2010 70 9 3463 3472 10.1158/0008-5472.CAN-09-4213 20406976
10. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Dyrskjot L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF, Cancer Res 2004 64 11 4040 4048 10.1158/0008-5472.CAN-03-3620 15173019
11. Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Dyrskjot L, Zieger K, Real FX, Malats N, Carrato A, Hurst C, Kotwal S, Knowles M, Malmstrom PU, de la Torre M, Wester K, Allory Y, Vordos D, Caillault A, Radvanyi F, Hein AM, Jensen JL, Jensen KM, Marcussen N, Orntoft TF, Clin Cancer Res 2007 13 12 3545 3551 10.1158/1078-0432.CCR-06-2940 17575217
12. Inhibition of bladder tumour growth by histone deacetylase inhibitor. Ozawa A, Tanji N, Kikugawa T, Sasaki T, Yanagihara Y, Miura N, Yokoyama M, BJU Int 2010 105 8 1181 1186 10.1111/j.1464-410X.2009.08795.x 19681894
13. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. Xu XS, Wang L, Abrams J, Wang G, J Hematol Oncol 2011 4 17 10.1186/1756-8722-4-17 21507255
14. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I, J Transl Med 2007 5 49 10.1186/1479-5876-5-49 17935615
15. Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Qu W, Kang YD, Zhou MS, Fu LL, Hua ZH, Wang LM, Urol Oncol 2010 28 6 648 654 10.1016/j.urolonc.2008.11.018 19181544
16. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Vallo S, Xi W, Hudak L, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA, Anticancer Drugs 2011 22 10 1002 1009 21822119
17. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers. Niegisch G, Knievel J, Koch A, Hader C, Fischer U, Albers P, Schulz WA, Urol Oncol 2012 31 8 1770 9 22944197
18. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP, Nat Med 1998 4 7 844 847 10.1038/nm0798-844 9662379
19. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. Fritzsche FR, Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Scholman K, Denkert C, Dietel M, Kristiansen G, BMC Cancer 2008 8 381 10.1186/1471-2407-8-381 19099586
20. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. Nocito A, Bubendorf L, Tinner EM, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jäger P, Fehr JL, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G, J Pathol 2001 194 3 349 357 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D 11439368
21. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boeve ER, Jobsis AC, Zwarthoff EC, J Clin Oncol 2003 21 10 1912 1921 10.1200/JCO.2003.05.073 12743143
22. Towards a knowledge-based Human Protein Atlas. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, Wernerus H, Björling L, Ponten F, Nat Biotechnol 2010 28 12 1248 1250 10.1038/nbt1210-1248 21139605
23. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder. Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, Simon R, Knuechel R, Pilarsky C, Hartmann A, Clin Cancer Res 2005 11 12 4415 4429 10.1158/1078-0432.CCR-05-0259 15958626
24. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS, J Clin Oncol 2010 28 16 2660 2667 10.1200/JCO.2009.25.0977 20421545
25. DNA microarray expression profiling of bladder cancer allows identification of noninvasive diagnostic markers. Mengual L, Burset M, Ars E, Lozano JJ, Villavicencio H, Ribal MJ, Alcaraz A, J Urol 2009 182 2 741 748 10.1016/j.juro.2009.03.084 19539325
26. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, Kimura W, J Clin Pathol 2007 60 11 1205 1210 10.1136/jcp.2005.029165 17720775
27. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN, Prostate 2004 59 2 177 189 10.1002/pros.20022 15042618
28. Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappaB activity. Floryk D, Huberman E, Cancer Res 2005 65 24 11588 11596 10.1158/0008-5472.CAN-05-1831 16357169
29. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM, Cancer Res 2001 61 23 8492 8497 11731433
30. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y, Endocrinology 2005 146 12 5365 5373 10.1210/en.2005-0359 16123169
31. Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines. Kang MR, Kang JS, Yang JW, Kim BG, Kim JA, Jo YN, Lee K, Lee CW, Lee KH, Yun J, Kim HM, Han G, Kang JS, Park SK, Oncol Lett 2012 3 1 113 118 22740865
32. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells. Earel JK Jr, VanOosten RL, Griffith TS, Cancer Res 2006 66 1 499 507 10.1158/0008-5472.CAN-05-3017 16397266
33. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M, Dietel M, Denkert C, Rocken C, Lancet Oncol 2008 9 2 139 148 10.1016/S1470-2045(08)70004-4 18207460
34. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ, Montironi R, Eur Urol 2004 45 5 606 612 10.1016/j.eururo.2003.11.011 15082203
35. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Muller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, Shariat SF, J Natl Cancer Inst 2009 101 2 114 119 10.1093/jnci/djn451 19141773
36. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. Quintero A, Alvarez-Kindelan J, Luque RJ, Gonzalez-Campora R, Requena MJ, Montironi R, Lopez-Beltran A, J Clin Pathol 2006 59 1 83 88 10.1136/jcp.2004.022939 16394286
37. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C, Clin Cancer Res 2008 14 6 1669 1677 10.1158/1078-0432.CCR-07-0990 18347167